Makarand Vaidya

Makarand Vaidya

Followers 1
Following 2
AT
Targeted Audience for This Study:# Healthcare insurance companies/payers# Healthcare IT service providers# Healthcare institutions/providers (hospitals, medical groups, physician practices, diagnostic centers, pharmacies, ambulatory centers, and outpatient clinics)# Venture capitalists# Healthcare BPO Vendors# Healthcare KPO Vendors# Government bodies# Corporate entities# Accountable care organizationsThe global healthcare claims management market was valued at USD 10.16 billion in 2017 and is projected to reach USD 13.93 billion by 2023, at a CAGR of 5.3% during the forecast period.Base year considered for the report is 2017 and the forecast period is 2018–2023.The key factors driving the growth of this market are increasing patient volumes, expanding health insurance market, growing importance of denials management, and declining reimbursement rates.Download PDF [email protected] https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=36752923By end user, the healthcare payers segment is expected to command the largest share of the market in 2018On the basis of end user, the market has been segmented into healthcare payers, healthcare providers, and other end users.The payers segment is expected to command the largest share of the market in 2018.The large share of this segment can be attributed to the mandate for insurance companies to meet the regulatory requirements and reduce unnecessary penalties and punishments.Major Objectives of this Study:# To define, describe, segment, and forecast the healthcare claims management market by component, delivery mode, type, end user, and region.# To provide detailed information about factors (drivers, restraints, opportunities, and challenges) influencing healthcare claims management market growth.# To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market.# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.# To forecast the size of the healthcare claims management market segments with respect to North America, Europe, Asia, and the Rest of the World (RoW).# To strategically analyze the market structure and profile the key players of the global healthcare claims management and comprehensively analyze their core competencies.# To track and analyze competitive developments such as agreements, collaborations, and partnerships; product deployments, product launches, and enhancements; acquisitions; and expansions in the healthcare claims management market.North America to dominate the market in 2018North America is expected to account for the largest share of the healthcare claims management market in 2018, followed by Europe.The large share of North America can be attributed to the high and growing HCIT investments in the region and the presence of regulatory mandates favoring the implementation of healthcare claims management solutions.
UK
However, the high cost of cell biology research is expected to restrain the growth of this market to a certain extent during the forecast period.The global reporter gene assays market is projected to reach USD 2.6 billion by 2024 from USD 1.6 billion in 2019, at a CAGR of 10.1%.Players in the global reporter gene assays market, such as Merck KGaA (Germany), Thermo Fisher Scientific (US), Promega Corporation (US), Abcam plc (UK), PerkinElmer (US), Danaher Corporation (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Geno Technology (US), GeneCopoeia, Inc. (US), InvivoGen (France), PromoCell (Germany), and Biotium (US) are focusing on increasing their presence in the high-growth markets through both organic as well as inorganic growth strategies of product launches, expansions, agreements, collaborations, and acquisitions.Download PDF [email protected]://www.marketsandmarkets.com/pdfdownloadNew.asp?id=20053198Merck is the leading player in the reporter gene assays market.With regard to providing innovative products, Merck invests a significant amount of its sales revenue in R In 2017, it invested around 14% of its sales revenue in R activities.This allows the company to extend its technological capabilities and provide superior-quality products, thereby helping it to achieve long-term growth.The company is also investing a large sum into its expansion projects to increase its production capacity and cater to a larger consumer base.Similar investments have been made by the company in the last few years.The acquisition of Sigma-Aldrich significantly enhanced the company’s global presence and broadened its portfolio in the reporter gene assays market.Recent Developments:# In 2018, Thermo Fisher acquired Advanced Bioprocessing business from BD, to expand Thermo Fisher Scientific’s cell-culture media products and strong technical services program.# In 2017, Becton, Dickinson and Company acquired C.R Bard (US).This acquisition advanced BD’s product offerings and global reach.# In 2018, Merck opened a new 3,800-square-meter laboratory in Singapore.# In 2018, Thermo Fisher Scientific (US) opened its Bioprocess design center in Shanghai.Thermo Fisher Scientific was the second-largest player in the global reporter gene assays market in 2018.
AT
The laboratory centrifuge market is expected to reach USD 1.2 billion by 2023 from USD 1.1 billion in 2018, at a CAGR of 2.8%.However, the market faces major challenges in the form of mechanical failure of equipment (caused due to improper maintenance of rotors) and the release of harmful chemicals in the centrifugation of certain substances.Download PDF [email protected] https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197749088These players have adopted various growth strategies, such as partnerships, agreements, and collaborations; and new product launches, to further expand their presence in the laboratory centrifuge market.Product launches have been the key growth strategies adopted players from 2016 to 2018, which helped them to innovate on their offerings and broaden their customer base.Some of the leading players who adopted this strategy include Thermo Fisher Scientific Inc. (US), Eppendorf AG (Germany), and Danaher Corporation (US).Recent Developments:# In 2016, Thermo Fisher Scientific launched Medifuge.# In 2016, Beckman Coulter partnered with Henry Ford Health System.This partnership aimed to enhance and streamline operations by fully automating the Henry Ford Hospital laboratory and modernizing the equipment at 12 other Henry Ford locations.# In 2018, Eppendorf launched Centrifuge 5425.Thermo Fisher Scientific Inc. is one of the leading players in laboratory centrifuges market.Thermo Fisher has a robust promotional strategy in place and participates in various trade exhibitions, seminars, and workshops to promote its products.
AT
The study involved four major activities to estimate the current size of the global active pharmaceutical products market. Exhaustive secondary research was done to collect information on the market, its peer markets, and its parent market. The global active pharmaceutical ingredient market is estimated to reach USD 245.2 billion by 2024 from USD 182.2 billion in 2019, at a CAGR of 6.1% during the forecast period.The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Thereafter, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.Major Growth Boosting Factors:The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years.Download PDF [email protected] https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=263“The captive API manufacturers segment estimated to account for the largest share in 2019.”Based on type of manufacturer, the active pharmaceutical products market can be divided into captive API manufacturers and merchant API manufacturers. In 2019, the captive API manufacturers segment is expected to account for the largest share of the APIs market.
UK
Years considered for this report:# 2016 – Base Year# 2017 – Estimated Year# 2022 – Projected YearThe global poultry diagnostics market is estimated to reach USD 495.3 Million by 2022 from USD 300.6 Million in 2017, at a CAGR of 10.5%.The majority of the demand for testing kits such as ELISA and PCR tests is driven by the increase in disease outbreaks in poultry, rising prevalence of zoonotic diseases, and growing demand for poultry-derived food products.Target Audience:# Veterinary diagnostics manufacturers# Veterinary diagnostics distributors# Animal health research and development (R) companies# Veterinary reference laboratories# Government associations# Market research and consulting firms# Venture capitalists and investorsDownload PDF [email protected] https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134560458On the basis of product, the market has been further segmented by test type and disease type.This can be attributed to the wide use of ELISA tests for preliminary screening of all avian diseases coupled with their high sensitivity, specificity, and cost-effective nature.By service, the market is segmented by bacteriology, virology, and parasitology.This is attributed to the regular bacterial testing on poultry undertaken by regions like Europe and Asia-Pacific to detect and prevent the spread of zoonotic diseases like salmonellosis, pasteurellosis, and mycoplasmosis.Geographically, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.Growth in this region can be attributed to the large livestock population in this region, growing demand of poultry-derived food products, increasing awareness about animal health, and growing per capita animal health expenditure, especially in India and China.Request Sample [email protected] https://www.marketsandmarkets.com/requestsampleNew.asp?id=134560458The major players in the poultry diagnostics market include IDEXX Laboratories, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Zoetis, Inc. (U.S.), QIAGEN N.V. (Netherlands), GD Animal Health (Netherlands), IDvet (France), AffiniTech, LTD. (U.S.), AgroBioTek Internacional (Honduras), and BioChek (Netherlands).The leading position of IDEXX Laboratories, Inc. in this market is mainly attributed to its strong product portfolio, wide geographic presence, and strong services network across the globe.The company also has a diversified revenue system, which helps it to sustain its leading position in the market.
AT
The study involved four major activities in estimating the current size for the Air Quality Index Monitoring Market.Exhaustive secondary research was done to collect information on the market and its different subsegments.The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.The global air quality monitoring system market is projected to reach USD 6.0 billion by 2025 from USD 4.3 billion in 2019, at a CAGR of 5.6%.The major factors driving the growth of the AQMS market include the supportive government regulations for effective air pollution monitoring and control associated with the rising levels of air pollution, initiatives towards the development of environment-friendly industries, and increasing public awareness related to the environmental and healthcare implications of air pollution.Download PDF [email protected] https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=183784537Government agencies and academic institutes held the largest share of the AQMS market in 2019Based on end-user, the air quality monitoring system market is segmented into government agencies and academic institutes, commercial and residential users, petrochemical industry, power generation plants, pharmaceutical industry, smart city authority, and other end users.The government agencies and academic institutes segment accounted for the largest share in 2018.The large share of this segment can be attributed to the presence of stringent environmental regulations, rising government investments for effective AQM, and increased installation of AQM stations worldwide.Recent Developments:# In March 2019, Thermo Fisher Scientific (US) launched the TriPlus 500 Gas Chromatography Headspace Autosampler.# In February 2018, TSI (US) acquired 3M’s (US) Personal Safety Division, which includes offerings focused on noise, environmental, and heat stress monitoring.TSI also acquired 3M's Oconomowoc, Wisconsin facility.# In November 2017, Emerson (US) collaborated with Fluenta (Norway) to provide ultrasonic flare gas measurement solutions for the oil & gas and chemical industries.
UK
Hepatitis testing refers to the diagnostic procedures performed to determine what genotype of hepatitis is causing the disease and what treatment is best suited.As different hepatitis viruses cause similar symptoms, it is important to run a series of diagnostic tests to identify the virus.The global hepatitis testing market is valued at 2.54 billion in 2017 and expected to grow at CAGR of 4.9% to USD 3.37 billion by 2023 during the forecast period.The base year considered for the study is 2017, and the forecast for the market size is provided for the period between 2018 and 2023.Increasing number of blood transfusions & donations, high burden of hepatitis worldwide, benefits offered by point of care instruments & kits, and initiatives taken by government and non-government organizations are the major factors driving this market.Download PDF [email protected] https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=139802887The hepatitis C segment is expected to grow at the highest rate in the next five yearsOn the basis of disease type, the market is segmented into hepatitis B, hepatitis C, and other hepatitis disease.The hepatitis C segment is projected to grow at the highest CAGR during the forecast period.This growth is primarily attributed to the increasing incidence of HCV infections and limited vaccination coverage.Target Audience:# Blood banks# Pathologists and pathology laboratories# Distributors of IVD products# Research institutes# Hospitals and clinics# Healthcare institutions# Group purchasing organizations (GPOs)# Market research and consulting firmsThe ELISA segment is expected to hold the largest market share during the forecast periodOn the basis of technology, the hepatitis test solution/diagnosis market is segmented into ELISA, rapid diagnostics test, PCR, INAAT, and other technologies.
UK
Research Methodologies Used for Market Size Estimation:Primary Research:The tracheostomy devices market comprises several stakeholders such as hospitals and surgical centers, ambulatory care centers, home care settings, and research laboratories & academic institutes.The demand side of this market is characterized by the increasing prevalence of respiratory diseases & disorders, technological advancements, and rising patient demand for home care services.Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.Secondary Research:In the secondary research process, various secondary sources, such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.Download PDF [email protected] https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=79626751The study involved four major activities in estimating the current size of the tracheostomy products market.The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.After that, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.Recent Developments:# In February 2019, Medtronic Plc entered into a partnership with Medical University of South Carolina (US) for the development of better and affordable healthcare solutions (including tracheostomy procedure for breathing assistance) for patients.# In October 2017, Medtronic Plc established the Chengdu Innovation Center at Singapore for cross-disciplinary clinical training and RHospitals & surgical centers segment accounted for the largest share of the tracheostomy products market, by the end-user, in 2018Hospitals & surgical centers were the largest application segment of the tracheostomy devices industry, and this trend is expected to continue during the forecast period.A large number of private enterprises are taking steps to cater to the needs of modern, which has resulted in the large share of this segment.
UK
Critical questions the report answers:# Where will all these developments take the industry in the long term?# What are the upcoming trends for the autoinjector market, and Needle-Free Injectors market market?# Which segment provides the most opportunity for growth?# Who are the leading vendors operating in this market?# What are the opportunities for new market entrants?The Injectable Drug Delivery Market is projected to reach USD 902.3 billion by 2027 from USD 362.38 billion in 2016, at a CAGR of 11.5% during the forecast period.Growth in this market is mainly driven by increasing prevalence of chronic diseases, rising aging population, increasing use of biologics, and increasing number of needlestick injuries.On the other hand, growing use of alternative delivery methods, safety concerns, and risk of transmission of blood-borne infections and needlestick injuries may hinder the growth of the market.The large share of this market segment can be attributed majorly due to its good barrier properties as compared to other types of packaging; moreover, they offer better protection at a lower cost.Ease of transportation and low cost of manufacturing are the factors driving the growth in this segment.Based on region, the injectable drug delivery market is segmented into North America, Europe, Asia, and the Rest of the World (RoW).North America is further subsegmented into the U.S. and Canada; while Europe is further subsegmented into Germany, France, the U.K., Italy, Spain, and the Rest of Europe (RoE); Asia is further subsegmented into Japan, China, India, and the Rest of Asia (RoA).Recent Developments:# In 2016, Gerresheimer extended its partnership with Taisei Medical Co. Ltd. (Japan) with an aim to market its ClearJect syringes and provide technical support to its customers.
AT
Drug discovery is the early phase in which target identification, target validation, hit-to-lead identification, lead optimization, and candidate validation takes place to deliver any suitable molecule or candidate for drug development.The drug discovery services market is projected to reach USD 19.1 billion by 2025 from USD 10.7 billion in 2020, at a CAGR of 12.1%  from 2020 to 2025.Other MnM proprietary reports were also referred to estimate the market size.The research methodology used to estimate the market size includes the following:# The key players in the industry and markets have been identified through extensive secondary research.# The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.# All percentage shares split, and breakdowns have been determined using secondary sources and verified through primary sources.Drug discovery services are provided by contract research organizations (CROs) to pharmaceutical companies (pharmaceutical companies outsource these services to CROs).Download PDF [email protected] https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=138732129Major Industry Leaders:The drug discovery services market is fragmented and is dominated by various players as per the segments.The major players operating in this market are Laboratory Corporation of America Holdings (US), Albany Molecular Research, Inc. (US), Charles River Laboratories International, Inc. (US), Evotec SE (Germany), Eurofins Scientific (Luxembourg), WuXi AppTec (China), GenScript Biotech Corporation (China),  and  Thermo Fisher Scientific, Inc. (US) among others.Recent Developments:# In 2019, Charles River (US) and CHDI Foundation, Inc. (US), Extended collaboration on drug discovery and development for Huntington’s Disease by five years.# In 2019, Laboratory Corporation of America Holdings’s (US) opened the Covance Drug Development segment opened a new R Center in Shanghai, China—its largest facility in the Asia Pacific.This will help the company to grow its business in China and the APAC.Laboratory Corporation of America Holdings (US)Laboratory Corporation of America Holdings is a leading player in the drug discovery services market.The company has pursued competitive strategies such as acquisitions and expansions to strengthen its presence in the drug discovery services market.
AT
The emergence of multifunctional excipients, shifting the focus of pharmaceutical manufacturing to emerging markets, and the growing biosimilars industry also present significant growth opportunities for market players.The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.In 2018, oral formulations accounted for a major share of the pharmaceutical excipients market, mainly because oral formulations are the most common route of drug delivery.Owing to the shrinking pipeline of new chemical entities (NCEs), companies are increasingly focusing on developing orally disintegrating tablets (ODTs) and other novel methods of oral drug delivery.There is also a growing trend towards sachet formulations.Key Questions Addressed in the Report:# Who are the top 10 players operating in the pharmaceutical excipients market?# What are the drivers, restraints, opportunities, and challenges in the pharmaceutical excipients market?# What are the industry trends as well as the current scenario in the pharmaceutical excipients market?# What are the growth trends in the pharmaceutical excipients market at the segmental and overall market levels?# How is the pharmaceutical excipients market performing in different regions across the globe?By functionality, the fillers and diluents segment is expected to account for the largest share of the pharmaceutical excipients market in 2019The fillers & diluents segment accounted for the largest share of the pharmaceutical excipients market in 2018.Oral formulations account for a majority share in the pharmaceutical industry, and as these formulations require fillers and diluents the most, this segment automatically has the majority share of the pharmaceutical excipients market.Recent Developments:# In April 2019, Colorcon, Inc. (US) signed an agreement with DuPont Nutrition and Biosciences (US) in order to enhance the current product portfolio of CR Alliance products.# In February 2019, Associated British Foods plc (UK) signed an agreement with Indchem International (India) under which, Indchem will distribute Associated British Food’s functional lipid excipient product line in the Indian market.# In January 2019, Croda International (UK) acquired Brenntag Biosector (Denmark) for its vaccine adjuvants portfolio which would be complementary to Croda’s pharmaceutical excipients portfolio.# In December 2018, Roquette Feres (France) signed an agreement with Thermo Fisher Scientific (US), which gives Thermo Fisher the right to distribute the product portfolio of Roquette in the US and Canada.Request Sample [email protected] https://www.marketsandmarkets.com/requestsampleNew.asp?id=956The Asia Pacific is expected to be the fastest growing the market in 2019In 2018, the Asia Pacific region was seen as the fastest growing region in the pharmaceutical excipients market.
AT
The study involved two major activities in estimating the current market size of the fill-finish manufacturing market.Exhaustive research was conducted to collect information on the market as well as its peer and parent markets.The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.The global fill-finish manufacturing market size is projected to reach USD 12.1 billion by 2025 from USD 7.5 billion in 2020, at a CAGR of 10.0% during the forecast period.The major factors driving the growth of this market include rising technological advancements in fill-finish manufacturing processes, the growth of the biopharmaceutical industry, and the rising adoption of prefilled syringes for parenteral dosage forms.
IT
Market growth can be attributed to increasing use of peptides in pharmaceutical drugs, increase in research activities and availability of funding for R, and the development of advanced peptide synthesizers.The base year considered for the study is 2017, and the forecast has been provided for the period between 2018 and 2023.Restraint:# Lack of a unified set of regulations for therapeutic peptidesOpportunity:# Emerging markets in the Asia Pacific region.Challenges:# Issues associated with the route of administration of peptide drugsDownload PDF [email protected] https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=158927365GenScript Biotech Corporation:GenScript accounted for the largest share of the market in 2017.The company has a broad product/services portfolio in peptide synthesis market and focuses on research and development activities to enhance its offerings.For Instance, in 2016 the company’s research and development expenses were approximately USD 9.5 million, 8.3% of the total revenue.Major Market Developments:# In 2018, CEM Corporation launched the Liberty PRIME, automated microwave peptide synthesizer.# In 2017, Merck acquired Grzybowski Scientific Inventions (GSI) (US).Sigma-Aldrich’s SAFC Commercial business is now a part of Merck’s Life Science segment.Merck KGAA:Merck held the second position in the peptide synthesis market in 2017.To leverage growth opportunities in the peptide synthesis market, Merck focuses on adopting organic as well as inorganic growth strategies.
AT
The major factors driving the growth of the sleep apnea devices market are primarily a large pool of undiagnosed sleep apnea patients, growing awareness about the ill effects of untreated sleep apnea, growing usage of oral appliances, technological advancements in sleep apnea devices, considerable venture capital funding, and an increasing number of companies venturing into sleep apnea and oral appliances markets.The global sleep apnea devices market is expected to reach USD 7.5 billion by 2024 from USD 4.5 billion in 2019 at a CAGR of 10.7%.The study involved four major activities in estimating the current market size for sleep apnea devices.Exhaustive secondary research was done to collect information on the market and its different sub-segments.The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.Thereafter market breakdown and data triangulation was used to estimate the market size of segments and sub-segments.Download PDF [email protected] https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=719The therapeutic devices segment accounted for the largest market share during the forecast period.On the basis of type, the sleep apnea devices market has been segmented into therapeutic devices and diagnostic devices.The key factors contributing to this growth are the increasing number of undiagnosed sleep apnea patients across the globe and the improving reimbursement scenario for these devices.
IN
The global medical equipment cooling market  is projected to reach USD 261 million by 2027 from USD 193 million in 2019, at a CAGR of 3.8%.Additionally, the growing global prevalence of cancer, increasing geriatric population, and growing number of diagnostic centers and hospitals are some of the other major factors driving the growth of this market.This study involved four major activities in estimating the current size of the medical equipment cooling market.Exhaustive secondary research was done to collect information on the market and its different subsegments.The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.Thereafter, market breakdown and data triangulation procedures were used to estimate the size of the segments and subsegments.Download PDF [email protected] https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=158980475Report Objectives:# To define, describe, and forecast the global medical equipment cooling market on the basis of type, compressor, configuration, application, end user, and region.# To provide detailed information regarding major factors influencing the growth of the market (such as drivers, opportunities, and industry-specific challenges).# To strategically analyze the micromarkets with respect to individual growth trends, future prospects, and contributions to the total market.# To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders.# To forecast the revenue of the market segments with respect to four main regions, namely, North America (the US and Canada), Europe (Germany, France, the UK, and RoE), Asia Pacific (China, Japan, India, and RoAPAC), and the Rest of the World.# To strategically profile the key players and comprehensively analyze their market shares and core competencies.# To track and analyze competitive developments such as new product launches; agreements, partnerships, and joint ventures; mergers & acquisitions; and research & development activities in the medical equipment cooling market.Asia Pacific to register highest growth in the medical eqipment cooling market during the forecast periodThe medical equipment cooling market is segmented into four regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World.Asia Pacific region is expected to register highest growth during the forecast period.
IN
Increasing incidence of renal disorders, growing incidence of other chronic disorders impacting renal function, rising awareness and adoption of preventive healthcare approaches, implementation of favorable government initiatives to promote renal health, rapid growth in the geriatric population, and advancements in biomedical research pertaining to kidney disorders are driving the growth of the global creatinine assay kits marketThe global creatinine assay kits market is expected to reach USD 245.4 Million by 2022 from USD 189.6 Million in 2017, at a CAGR of 5.3%.Agreements, acquisitions, and expansions accounted for the largest share of the overall growth strategies followed by key players between 2014 and 2017.Some of the companies that adopted this strategy include Thermo Fisher Scientific (US), Merck (Germany), Abcam (UK), Abbott Laboratories (US), and Cayman Chemical (US).Target Audience for this Report:# Creatinine assay kit manufacturers# Creatinine assay kit distributors# Hospitals# Research and consulting firms# Venture capitalists# Regulatory bodies# Academic centers# Teaching hospitals and academic medical centers (AMCs)# Contract manufacturing organizations (CMOs)# Contract research organizations (CROs)Download PDF [email protected] https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=73499229The creatinine assay kits market is highly fragmented in nature with many big and small players.Thermo Fisher Scientific was the leading player in the creatinine assay kits market in 2016.The leading position of the company can be attributed to its strong brand recognition, customer loyalty, and extensive product portfolio.The company has a strong geographic presence and a keen focus on increasing its reach and enhancing its distribution network.
UK
Major Objectives Behind This Study Are:# To define, describe, and forecast the global neurovascular devices market on the basis of product, disease pathology, and region.# To provide detailed information regarding major factors influencing growth of the market (drivers, restraints, and opportunities).# To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall market.# To analyze the opportunities in the market for key stakeholders and provide details of the competitive landscape for leading market players.# To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW).# To strategically profile the key market players and comprehensively analyze their market shares and core competencies.# To track and analyze competitive developments such as acquisitions, expansions, new product launches, agreements, and collaborations in the neurovascular devices/interventional neurology devices marketThe neurovascular devices market is expected to reach USD 2.62 billion by 2021 from USD 1.74 billion in 2016, at a CAGR of 8.6% from 2016 to 2021.Major factors driving the growth of this market include growing target patient population, ongoing product development & commercialization, favorable medical reimbursements, expansion of healthcare infrastructure across emerging markets, and growing market demand for effective neurovascular devices.Download PDF [email protected] https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=847Moreover, increasing number of researches in the field of neurovascular therapies, rising demand for minimally invasive neurosurgical procedures, and increasing awareness among neurosurgeons about minimally invasive surgical procedures provide significant growth opportunities in the market.However, stringent regulatory scenario and dearth of skilled neurosurgeons may hinder the growth of this market during the forecast period.Critical questions the report answers:# What are the emerging technologies for interventional neurology treatment ecosystem?What is their growth potential during next decade?# What are the key revenue generating pockets for major neurovascular devices market; and their future potential during next decade?# How competitive landscape is evolving in minimally invasive/interventional neurology devices industry?On the basis of disease pathology, the market is segmented into ischemic strokes, cerebral aneurysm, arteriovenous malformations & fistulas, and other diseases.The ischemic strokes segment is poised to be the fastest growing segment during the forecast period owing to growing incidence of ischemic stroke (coupled with exposure of larger proportion of global population to major risk factors such as smoking and diabetes), and increasing patient preference for minimally invasive therapeutic alternatives.Target Audience:# Original Equipment Manufacturers (OEMs)# Product Sales and Distribution Companies# Healthcare Service Providers (Hospitals and Surgical Centers)# Non-government Organizations# Government Regulatory Authorities# Research Laboratories and Academic Institutes# Clinical Research Organizations (CROs)# Research and Development Companies# Market Research and Consulting FirmsOn the basis of geography, this market is classified into four regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World.
UK
Factors such as advancements in NGS platforms, reduced cost of sequencing, and improving reimbursement scenario for NGS-based diagnostic tests are driving the growth of this market.This is a key restraint for market growth.[203 Pages Report] The NGS sample preparation market is projected to grow from USD 1.1 billion in 2019 to USD 2.7 billion by 2024, at a CAGR of 18.7% during the forecast period.The study used four major activities to estimate the current market size for the NGS sample preparation market.Exhaustive secondary research was done to collect information on the market and its different subsegments.The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.Thereafter, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.Download PDF [email protected] https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=69735098The diagnostics segment is estimated to grow at the highest CAGR during the forecast periodBased on application, the NGS sample preparation market is segmented into diagnostics, drug discovery, agricultural & animal research, and other applications.
IN
The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.However, the high costs associated with isolators and RABS is a factor expected to limit the growth of this market to some extent.The global fill-finish manufacturing market size is projected to reach USD 12.1 billion by 2025 from USD 7.5 billion in 2020, at a CAGR of 10.0% during the forecast period.The prominent players in the global fill-finish manufacturing market include Becton, Dickson and Company (US), Syntegon Technology GmbH (Germany), I.M.A.These players have adopted various growth strategies such as product launches, acquisitions, agreements, partnerships, and expansions to increase their presence in the global fill-finish manufacturing industry.Download PDF [email protected] https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=6249609Becton, Dickinson and Company (US) is the leading player in the global fill-finish manufacturing market.This subsegment reported an increase in revenue of approximately USD 7 billion in FY 2019 as compared to 2018.This increase indicates positive sales growth in pharmaceutical drug delivery systems, inclusive of prefilled syringes.It is expected to witness strong sales in the fill-finish manufacturing industry during the forecast period.These products are then placed in the market as drug/device combinations.Report Objectives:# To define, describe, segment, and forecast the global fill-finish manufacturing market by product, end user, and region.# To provide detailed information regarding the major factors influencing the growth of the market such as drivers, restraints, opportunities, industry-specific challenges, and trends.# To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall fill-finish manufacturing market.# To analyze market opportunities for stakeholders and provide details of the competitive landscape for market players.# To forecast the size of the fill-finish manufacturing market with respect to five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.# To strategically profile the key players in the market and comprehensively analyze their market rankings and core competencies.# To track and analyze competitive developments such as acquisitions, agreements, collaborations, partnerships, product launches, and expansions in the fill-finish manufacturing market.Syntegon Technology GmbH (Germany) is another leading player in the global fill-finish manufacturing market.
AT
The study involved 4 major activities in estimating the current market size for pharmaceutical excipients market.Exhaustive secondary research was done to collect information on the market as well as its peer and parent markets.The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.Thereafter, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.The report "Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohyrates, Petrochemicals) inorganic chemicals), Functionality (Fillers, Diluents, Coatings, Disintegrants), Formulation (Tablet, Capsule, Topical, Parenteral) - Global Forecast to 2025", The pharmaceutical excipients market is projected to reach USD 9.7 billion by 2025 from USD 6.9 billion in 2019, at a CAGR of 5.8%.Factors such as the growing pharmaceuticals industry coupled with advancements in functional excipients, rising adoption of orphan drugs, and increasing uptake of biopharmaceuticals, are driving the market for pharmaceutical excipients.Download PDF [email protected] https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=956The emergence of multifunctional excipients, shifting the focus of pharmaceutical manufacturing to emerging markets, and the growing biosimilars industry also present significant growth opportunities for market players.In 2018, oral formulations accounted for a major share of the pharmaceutical excipients market, mainly because oral formulations are the most common route of drug delivery.Owing to the shrinking pipeline of new chemical entities (NCEs), companies are increasingly focusing on developing orally disintegrating tablets (ODTs) and other novel methods of oral drug delivery.
1
FR
Growth in the environmental testing equipment analysis market can be attributed to factors such as the rising levels of environmental pollution worldwide, increasing government regulations and initiatives for environmental protection, privatization of environmental testing services, and increasing focus on wastewater treatment.On the other hand, high capital investments for accurate and sensitive analytical testing and lack of supporting infrastructure and skilled professionals are expected to limit market growth to a certain extent during the forecast period.Major Leaders:   The major players in the environmental testing equipment analysis market include Agilent Technologies (US), Thermo Fisher Scientific (US), Waters Corporation (US), Shimadzu Corporation (Japan), Bruker (US), PerkinElmer (US), SCIEX (a subsidiary of Danaher) (US), JEOL (Japan), Analytik Jena (Germany), and Merck KGaA (Germany).Download PDF [email protected] https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=149706080Different Growth Adopted by Major Players:The analysis of market developments between 2016 and 2018 showed that market players adopted growth strategies such as product launches, strategic acquisitions, expansions, partnerships, agreements, and collaborations to strengthen their product portfolios and maintain a competitive position in the environmental testing equipment analysis market.In 2017, Agilent technologies held the dominant position in the environmental testing equipment market.This can be attributed to the extensive product portfolio of analytical technologies, including chromatography, molecular spectroscopy, and mass spectrometry that the company offers.The firm strives to maintain its leading position by engaging in inorganic and organic growth strategies such as product launches, acquisitions, collaborations, and expansions.The increase in the revenue of the Life Sciences and Applied Markets segment (offering chromatography and spectrometry instruments) was led by its growth in applied markets such as environmental, chemical and energy, and food.
AT
This report provides a detailed overview of the major drivers, restraints, opportunities, and threat impacting the global top 10 bioprocess technology market along with the estimates and forecasts of the revenue and market share analysis.The global top 10 bioprocess technology market is expected to reach USD 71.03 Billion by 2021 from USD 39.30 Billion in 2016, at a CAGR of 12.4% from 2016 to 2021.Rapid growth in pharmaceutical and biotechnology industries, growth in the number of new drug launches, strong trend of R in life sciences research, increasing government support for pharmaceutical and biotechnology industries, and rising prevalence of chronic diseases are the key factors driving the growth of this market.Download PDF [email protected] https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=30722776The global top 10 bioprocess technology market is segmented on the basis of type and region.On the basis of type, the market is segmented into cell culture, cell expansion, cell counting, flow cytometry, single-use bioprocessing, cell line development, virus filtration, biologics safety testing, pyrogen testing, and tangential flow filtration.In 2016, the cell culture segment is expected to account for the largest share of the global top 10 bioprocess technology market.Target audience for this report:# Academic Research Institutes# Pharmaceutical Companies# Biotechnology Companies# Bioprocess Technology Manufacturing Companies# Contract Research Organizations (CROs)# Market Research & Consulting Firms On the basis of region, the market is segmented into North America, Europe, Asia, and RoW.In 2016, the North American region is expected to account for the largest share of the global top 10 bioprocess technology market.This growth can be attributed to the increased R spending by pharmaceutical and biotechnology companies in this region.The prominent players in the top 10 bioprocess technology market include GE Healthcare (U.S.), Merck Millipore (Germany), Thermo Fisher Scientific, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Danaher Corporation (U.S.), Lonza Group AG (Switzerland), Sartorius Stedim Biotech S.A (France), Corning, Inc.(U.S.), Bio-Rad Laboratories (U.S.), and Charles River Laboratories (U.S.).Request Sample [email protected] https://www.marketsandmarkets.com/requestsampleNew.asp?id=30722776An analysis of the market developments between 2014 and 2016 revealed that product launches and agreements & collaborations was the most important growth strategy adopted by market leaders.The other important growth strategy adopted by players in this market was mergers & acquisitions, expansions, and product approvals.
1
UK
In 2020, the respiratory care devices market reached USD 58.1 billion.The growth of this market is mainly attributed to the high prevalence of respiratory diseases, rising aging population across the globe, high prevalence of smoking, rising urbanization and pollution levels, increasing incidence of preterm births, and lifestyle changes.The global respiratory care devices Market is expected to reach USD 29.9 billion by 2025 from USD 16.0 billion in 2019, at a CAGR of -12.5% during the forecast period of 2020 to 2025.Thus, the respiratory care devices market witnessed a CAGR of 261.1% between 2019 and 2020.However, a lack of awareness leading to a large underdiagnosed and undertreated population and the harmful effects of specific respiratory care devices on neonates have hampered market growth to an extent.Download PDF [email protected]://www.marketsandmarkets.com/pdfdownloadNew.asp?id=368Objectives of the Study:# To define, describe, and forecast the respiratory care devices market based on type, indication, end user, and region.# To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges).# To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the total market# To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders.# To forecast the size of the market segments with respect to five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.# To profile key market players and comprehensively analyze their product portfolios, market shares, and core competencies.# To track and analyze competitive developments, such as product launches, expansions, acquisitions, agreements, and collaborations in the respiratory care devices market.North America was the largest regional market forbioanalytical testing services in 2019The global bioanalytical testing services market is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.The large share of North America region is mainly attributed to the strong presence of a large number of major manufacturers, its rising geriatric population, high prevalence of smoking and respiratory diseases, and the presence of a highly developed healthcare system.Recent Developments:# In April 2020, Philips launched the PHILIPS RESPIRONICS E30 VENTILATOR.This will enable company to help healthcare professionals by providing superior quality ventilators.# In January 2020, Masimo Corporation acquired Connected Care Business from NantHealth (US).
1
UK
The demand for healthcare IT solutions and services is driven by government mandates & support for healthcare IT solutions, rising use of big data in healthcare, high returns on investment for healthcare IT solutions, and the need to curtail escalating healthcare costs.Key Questions Addressed in the Report:# Who are the top 10 players operating in the healthcare IT market?# What are the driving factors, restraints, opportunities, and challenges in the market?# What are the industry trends as well as the current scenario in the healthcare IT market?# What are the growth trends in the market at the segmental and overall market levels?“The healthcare payer fraud detection analytics market is estimated to witness high growth from 2019 to 2024”Based on healthcare payers solutions, the market is segmented into claims management, customer relationship management, payer fraud analytics solutions, provider network management, pharmacy audit & analysis, member eligibility management, population health management solutions, and payment management solutions.Download PDF [email protected] https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=252The fraud analytics solutions is estimated to witness high growth from 2019 to 2024.The growing incidence of healthcare fraud (leading to the increasing healthcare costs and rising insurance premiums) has compelled payers and other stakeholders in the market to increase their focus on adopting data analytics software for faster and efficient fraud detection and prevention.“The healthcare provider solutions segment is estimated to grow at the highest CAGR during the forecast period”The healthcare provider solutions segment is estimated to witness the highest growth in the Healthcare IT market, by product and services, during the forecast period.Growth in this segment is attributed to the increasing demand for improved patient safety and patient care, stringent regulations regarding healthcare provider solutions, and the need for integrated healthcare systems.Recent Developments:# In 2019, Philips launched Cares Aging & Caregiving service.# In 2018, Change Healthcare  launched Dx Gap Advisor.# In 2017, Optum acquired DaVita Medical Group (US).The acquisition of DaVita enhanced Optum’s physician-led primary, specialty, in-home, and surgery-care delivery services business.# In 2017, Cognizant acquired TMG Health (US) to expand its business process-as-a-service solutions for government and public health programs.# In 2018, Optum collaborated with Humana (US), MultiPlan (US)  and Quest Diagnostics (US) to form a group to explore the blockchain technology to improve data quality and reduce administrative costs in healthcare.“North America dominated the Healthcare IT market in 2018”The Healthcare IT market is broadly segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.North America accounted for the largest share of the Healthcare IT market in 2018.
AT
Growth in the Medical Equipment Cooling Market can be attributed to factors such as economic benefits offered by cooling systems, technological advancements in diagnostic imaging modalities, rising geriatric population, and a growing number of diagnostic centers and hospitals.On the other hand, the risk of corrosion in cooling systems may also pose a major challenge to market growth in the coming years.The global medical equipment cooling market is projected to reach USD 233 million by 2024 from USD 193 million in 2019, at a CAGR of 3.8%.The major players operating in the medical equipment cooling market include Glen Dimplex Group (Ireland), Legacy Chiller Systems Inc. (US), Filtrine Manufacturing Company, Inc. (US), Laird Technologies, Inc. (US), Cold Shot Chillers (US), KKT Chillers (Germany), General Air Products, Inc. (US), Drake Refrigeration, Inc. (US), Lytron, Inc. (US), Motivair Corporation (US), American Chillers (US), Parker Hannifin Corp (US), Whaley Products Inc. (US), Johnson Thermal Systems (US), and Haskris (US).An analysis of the market developments between 2016 and 2018 revealed that several growth strategies such as product enhancements and expansions were adopted by market players to strengthen their product portfolios and maintain a competitive position in the medical equipment cooling market.Recent Developments:# In 2018, Laird Technologies (US) enhanced its Tunnel Series TEA which offers an expanded line of cooling capacities ranging up to 100 watts.# In 2016, KKT Chillers (Germany) established a new service center in Shanghai, China, to meet the increasing demand for chillers in the region.Download PDF [email protected] https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=158980475Glen Dimplex (Ireland) is a leading player in the medical equipment cooling systems market.The company manufactures and delivers a wide range of chillers and cooling solutions across the medical, food packaging, plastics, and semiconductor industries in the US and internationally.Glen Dimplex offers active and passive cooling solutions either in integrated or stand-alone modes, for a wide range of medical equipment such as CT, MRI, linear accelerators, and medical laser technology.The company has a global presence and a prominent after-sales service network, with locations across the US, China, Germany, and Ireland.Key Questions Addressed by the Report:# What are the growth opportunities related to the adoption of medical equipment cooling across major regions in the future?# Emerging countries have immense opportunities for the growth and adoption of medical equipment cooling modalities.
UK
The study involved four major activities for estimating the size of the Animal Parasiticides Market.Exhaustive secondary research was done to collect information on the market, including its peer markets.The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.Both top-down and bottom-up approaches were employed to estimate the complete market size.After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.The report "Animal Parasiticides Market by Product (Ectoparasiticides, Endectocide (Ear Tags, Tablets, Dips, Injectables, Spot-on, Collars) Animal (Dogs, Cats, Cattle, Sheep, Goats, Horses) End-user (Veterinary Hospitals) - Global Forecast to 2025", is projected to reach USD 13.7 billion by 2025 from USD 9.7 billion in 2020, at a CAGR of 7.2% during the forecast period.The base year considered for the study is 2019, while the forecast period is 2020 to 2025.By animal type, companion animals held the highest growth of the animal parasiticides market in 2019On the basis of animal type, companion animals accounted for the highest growth in this market.
IT
Target Audience:# Blood banks# Pathologists and pathology laboratories# Distributors of IVD products# Research institutes# Hospitals and clinics# Healthcare institutions# Group purchasing organizations (GPOs)# Market research and consulting firmsThe report "Hepatitis Test Solution/Diagnosis Market by Disease Type (Hepatitis B, HCV, HAV, HDV), Technology (ELISA, RDT, PCR, Transcription Mediated Amplification), End User (Hospitals, Diagnostic Laboratories, Blood Banks, Nursing Homes) - Global Forecast to 2023", The global hepatitis test solution/diagnosis market is expected to reach USD 3.37 billion by 2023 from USD 2.66 billion in 2018, at a CAGR of 4.9% during the forecast period (2018–2023).Increasing number of blood transfusions & donations, high burden of hepatitis worldwide, benefits offered by point of care instruments & kits, and initiatives taken by government and non-government organizations are the major factors driving this market.Research Methodology Used:Top-down and bottom-up approaches were used to validate the size of the global hepatitis test solution/diagnosis market and estimate the size of various other dependent submarkets.Major players in the market were identified through secondary research, and their market revenues were determined through primary and secondary research.Secondary sources include annual reports, press releases, and investor presentations of companies; white papers; medical journals; certified publications; articles from recognized authors; gold standard and silver standard websites; directories; and databases.In-depth interviews were conducted with various primary respondents, such as key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as to assess future prospects.Download PDF [email protected] https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=139802887The hepatitis C segment is expected to grow at the highest rate in the next five yearsOn the basis of disease type, the market is segmented into hepatitis B, hepatitis C, and other hepatitis disease.This growth is primarily attributed to the increasing incidence of HCV infections and limited vaccination coverage.The ELISA segment is expected to hold the largest market share during the forecast periodOn the basis of technology, the hepatitis test solution/diagnosis market is segmented into ELISA, rapid diagnostics test, PCR, INAAT, and other technologies.
UK
The growth of this market is majorly driven by the launch of new products and favorable reimbursement scenario.However, the shift toward minimally invasive surgeries and adverse effect of hemostats are the major factors restraining the growth of this market.The report "European Hemostats & Sealants Market by Brand (Hemopatch [Baxter], Tachosil [Takeda], Veriset [Medtronic], Avitene [C.R Bard], Sangustop [B Braun], Lyostypt [B Braun]), Country (Germany, Uk, France, Italy & Spain) - Forecast to 2027", The hemostats and sealants (focused products) market is projected to reach USD 109 million by 2027 from USD 63 million in 2019, at a CAGR of 7.0%.The study involved four major activities to estimate the current size of the hemostats and sealants (focused brands) market.Exhaustive secondary research was conducted to collect information on the market and its different subsegments.The next step was to validate these findings, assumptions, and sizing estimates with industry experts across the value chain through primary research.Based on focused products, Tachosil is projected to register the highest growth during the forecast periodBased on focused products, the market is segmented into Tachosil, Lyostypt, Sangustop, Veriset, Avitene, and Hemopatch.
AT
The report "Human Liver Models Market by Drug Discovery Platform (Non-alcoholic Fatty Liver Organoids, Liver-on-a-chip, 2D Models, Animal Models, 3D Bioprinting), and Region (North America, Europe, Asia Pacific, Rest of the World) - Global Forecast to 2022", The global human liver models market is expected to reach USD 2.56 Billion by 2022 from USD 1.35 Billion in 2017, at a CAGR of 13.6% during the forecast period (2017-2022).Objectives of the Study:# To define, measure, and describe the global human liver model market by type and region.# To provide detailed information about the major factors influencing market growth (drivers, restraints, challenges, and opportunities).# To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market.# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.# To forecast the size of market segments in North America, Europe, Asia Pacific, and RoW.The key factors driving the growth of this market include growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of liver models, growing initiatives to increase awareness about liver organoids, increasing research activities on liver organoids, increasing prevalence of non-alcoholic fatty liver disease, and growing need for the early detection of drug toxicity to minimize financial losses due to late-stage drug failure.Download PDF [email protected] https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171046468Animal models accounted for the largest share of the market in 2017The human liver models market is segmented on the basis of type into liver organoids, liver-on-a-chip, 2D models, animal models, and 3D bioprinting.In 2017, the animal models segment accounted for the largest share of the global market.The growth in the biosimilars market is expected to boost the preclinical market as the development of biosimilars and biopharmaceuticals requires an understanding of the mechanism of action, quantification of pharmacological effects, and interpretation of toxicological data.Preclinical research also helps in securing a clear definition of targets.Target Audience:# Pharmaceutical and biotechnology companies# Chemical companies# Cosmetic product manufacturers, suppliers, and distributors# Healthcare providers and diagnostic laboratories# Manufacturers of 3D Cell Culture products# Food & beverage manufacturers# Contract research organizations (CROs)# Research institutes/universities# Research and consulting firms# Venture capitalistsMoreover, as the patents for many blockbuster drugs are set to expire by 2020, the demand for biosimilars and preclinical services is likely to increase.The rising demand for preclinical services, in turn is expected to drive the demand for animal models.North America held the largest share of the market in 2017In 2017, North America accounted for the largest share of the human liver models market, followed by Europe.The market for human liver models in this region is driven by the presence of a well-established life sciences industry, growing awareness about the organoids technology, favorable government initiatives, growing incidence of NAFLD, and unavailability of livers for transplantation, increased research spending, rising focus on tissue culture-based clinical diagnostics, and the availability of skilled professionals.Request Sample [email protected] https://www.marketsandmarkets.com/requestsampleNew.asp?id=171046468Major Leaders of the Industry:The major players in the global human liver model market are Emulate (US), Ascendance Bio (US), HìREL (US), CN Bio (UK), Organovo (US), and Cyfuse Biomedical (Japan).CN Bio held the leading position in the global liver-on-a-chip market in 2016.
UK
This study involved the extensive use of both primary and secondary sources.The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.The report "Topical Drug Delivery Market by Type (Semisolids (Creams, Ointments, Gels, Lotions), Liquids, Solids, Transdermal Products), Route (Dermal, Ophthalmic, Rectal, Vaginal, Nasal), Facility of Use (Homecare, Hospital, Burn Center) - Global Forecast to 2024", is projected to grow at a CAGR of 5.7% during the forecast period to reach USD 123.2 billion by 2024 from USD 93.2 billion in 2019.Factors such as the high prevalence of skin disease, rising incidence of eye diseases, high incidence of burn injuries, and the growing incidence of diabetes are driving the growth of the topical drug delivery market during the forecast period.Critical questions answered in the report:# How will the current technological trends affect the market in the long term?# What are the reasons contributing to the growth of the semi-solid market?# Which regions are likely to grow at the highest CAGR?# What are the challenges hindering the adoption of topical drug delivery devices?# What are the growth strategies being implemented by major market players?Download PDF [email protected] https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=124871717Research Methodology Opted:Primary Research:In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report.The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the topical drug delivery market.The primary sources from the demand side included industry experts, such as researchers and scientists, and industry experts from medical devices companies.Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.Recent Developments:# In April 2019, Crescita Therapeutics signed an out-licensing agreement with Cantabria labs for the sales and distribution of its topical Pliaglis formulation in Italy, Portugal, France, and Spain.# In November 2018, Bausch Healthcare expanded its manufacturing facility in Rochester (Ireland) to support and fulfill the demand of its topical eye health products.Secondary Research:The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D Hoovers), white papers, annual reports, companies house documents, investor presentations, and SEC filings of companies.
More

Top